JP2023526754A5 - - Google Patents
Info
- Publication number
- JP2023526754A5 JP2023526754A5 JP2022563894A JP2022563894A JP2023526754A5 JP 2023526754 A5 JP2023526754 A5 JP 2023526754A5 JP 2022563894 A JP2022563894 A JP 2022563894A JP 2022563894 A JP2022563894 A JP 2022563894A JP 2023526754 A5 JP2023526754 A5 JP 2023526754A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- atazanavir
- cycloprolylglycine
- artemether
- twice daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063012432P | 2020-04-20 | 2020-04-20 | |
| US63/012,432 | 2020-04-20 | ||
| US202063018768P | 2020-05-01 | 2020-05-01 | |
| US63/018,768 | 2020-05-01 | ||
| US202063032116P | 2020-05-29 | 2020-05-29 | |
| US63/032,116 | 2020-05-29 | ||
| US202063037373P | 2020-06-10 | 2020-06-10 | |
| US63/037,373 | 2020-06-10 | ||
| US202063041812P | 2020-06-19 | 2020-06-19 | |
| US63/041,812 | 2020-06-19 | ||
| US202163170350P | 2021-04-02 | 2021-04-02 | |
| US63/170,350 | 2021-04-02 | ||
| PCT/US2021/027848 WO2021216385A1 (en) | 2020-04-20 | 2021-04-17 | Methods for the prophylaxis and treatment of covid and covid-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526754A JP2023526754A (ja) | 2023-06-23 |
| JP2023526754A5 true JP2023526754A5 (enExample) | 2024-04-30 |
Family
ID=78270185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563894A Pending JP2023526754A (ja) | 2020-04-20 | 2021-04-17 | Ｃｏｖｉｄ および ｃｏｖｉｄ－１９ の予防と治療の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12239629B2 (enExample) |
| EP (1) | EP4138906A4 (enExample) |
| JP (1) | JP2023526754A (enExample) |
| AU (1) | AU2021259185A1 (enExample) |
| BR (1) | BR112022021304A2 (enExample) |
| CA (1) | CA3179317A1 (enExample) |
| GB (3) | GB2613460B (enExample) |
| WO (1) | WO2021216385A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2613460B (en) | 2020-04-20 | 2025-07-23 | Lloyd Hung Loi Tran | Pharmaceutical Compositions for use in methods for the prophylaxis or treatment of COVID such as COVID-19; and compound for use in the treatment of a |
| JP2023524522A (ja) * | 2020-05-01 | 2023-06-12 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． | 抗ｃｏｖｉｄ－１９剤としてのｅタンパク質チャネル遮断薬およびｏｒｆ３阻害剤 |
| CN118354775A (zh) * | 2021-10-06 | 2024-07-16 | 麦蒂恩斯株式会社 | 包含依法韦仑及氟西汀作为有效成分的用于预防或治疗病毒感染疾病的药物组合物 |
| WO2023080753A1 (ko) * | 2021-11-05 | 2023-05-11 | 주식회사 지투지바이오 | 비경구 병용투여용 약학적 키트 |
| WO2023086547A1 (en) * | 2021-11-12 | 2023-05-19 | Albert Einstein College Of Medicine | Cell impermeable kinase inhibitors to treat sars-cov-2 and/or hsv viral infections |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003039487A2 (en) | 2001-11-09 | 2003-05-15 | Neuronz Limited | Cyclo(prolyl-glycine) and methods of use to treat neural disorders |
| US7232798B2 (en) | 2001-11-13 | 2007-06-19 | Tran Loi H | Neuroprotection and neuroegenisis by administering cyclic prolyl glycine |
| US7842719B2 (en) * | 2002-10-31 | 2010-11-30 | Kemin Foods, L.C. | Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus |
| KR101621100B1 (ko) | 2007-03-30 | 2016-05-13 | 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 | 백신에 유용한 약독화 바이러스 |
| EP2581081A3 (en) * | 2007-06-01 | 2013-07-31 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
| EP3843768A4 (en) * | 2018-05-15 | 2022-11-23 | Tran, Lloyd Hung Loi | THERAPEUTIC COMPOSITION AND METHODS OF USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT, DEPRESSION AND MENTAL DISORDERS |
| US10980756B1 (en) * | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| IL297211B2 (en) * | 2020-04-16 | 2025-12-01 | Mereo Biopharma 4 Ltd | Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency |
| GB2613460B (en) * | 2020-04-20 | 2025-07-23 | Lloyd Hung Loi Tran | Pharmaceutical Compositions for use in methods for the prophylaxis or treatment of COVID such as COVID-19; and compound for use in the treatment of a |
| CN111803491A (zh) * | 2020-07-24 | 2020-10-23 | 中国人民解放军军事科学院军事医学研究院 | 青蒿素类化合物在治疗冠状病毒感染方面的应用 |
| CN114246858A (zh) * | 2020-09-21 | 2022-03-29 | 北京化工大学 | 青蒿素类化合物在治疗和预防冠状病毒感染中的应用 |
-
2021
- 2021-04-17 GB GB2217355.3A patent/GB2613460B/en active Active
- 2021-04-17 CA CA3179317A patent/CA3179317A1/en not_active Abandoned
- 2021-04-17 EP EP21793162.5A patent/EP4138906A4/en active Pending
- 2021-04-17 AU AU2021259185A patent/AU2021259185A1/en not_active Abandoned
- 2021-04-17 WO PCT/US2021/027848 patent/WO2021216385A1/en not_active Ceased
- 2021-04-17 JP JP2022563894A patent/JP2023526754A/ja active Pending
- 2021-04-17 GB GB2416046.7A patent/GB2632086A/en active Pending
- 2021-04-17 BR BR112022021304A patent/BR112022021304A2/pt not_active Application Discontinuation
-
2022
- 2022-10-18 US US18/047,432 patent/US12239629B2/en active Active
-
2024
- 2024-11-01 GB GB2416189.5A patent/GB2644651A/en active Pending
-
2025
- 2025-01-25 US US19/037,137 patent/US20250319060A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526754A5 (enExample) | ||
| RU2314810C2 (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| US20080096832A1 (en) | Method for Improving the Pharmacokinetics of an NNRTI | |
| GB2613460A (en) | Methods for the prophylaxis and treatment of Covid and Covid-19 | |
| JP2006506378A5 (enExample) | ||
| JP2017510607A5 (enExample) | ||
| ZA202201465B (en) | Long-lasting formulation containing rivastigmine, and method for preparing same | |
| DK166479B (da) | Anvendelse af fluoxetin, norfluoxetin eller et farmaceutisk acceptabelt salt af fluoxetin eller norfluoxetin til fremstilling af et laegemiddel med anxiolytisk virkning | |
| KR20140074270A (ko) | 조합 als 치료법 | |
| CA2313270A1 (en) | Use of deferiprone in treating and preventing iron-induced cardiac disease | |
| JP2016505050A5 (enExample) | ||
| CA2386547C (en) | Orally disintegrating composition comprising mirtazapine | |
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| JPH03170475A (ja) | 抑うつ症治療剤 | |
| KR20100124860A (ko) | 독소필린을 포함하는 변형 방출 조성물 | |
| JP2023539847A5 (enExample) | ||
| JP2018502168A5 (enExample) | ||
| JP2023554354A5 (enExample) | ||
| JP2006508993A5 (enExample) | ||
| JPS62267227A (ja) | 血中尿酸濃度の低下用医薬 | |
| US20070244102A1 (en) | Combination of Dermaciclane and Opoids as Analgesics | |
| IL312456A (en) | Treatment of major depressive disorder | |
| JPH0848639A (ja) | 改善された血圧上昇薬 | |
| CN116322688A (zh) | 用于治疗疟疾的固定剂量的联合用药 |